-
-
-
-
-
-
-
Astellas to Present Data on Long-Term Outcomes and Clinical Use of Its Portfolio Across Disease Stages at ASCO 2026
-
-
-
-
-
-
-
Pfizer advises shareholders to reject Tutanota mini-tender offer
-
-
-
-
-
-
-
Pfizer's BRAFTOVI shows improved survival in colorectal cancer trial
-
-
-
-
-
-
-
Pfizer's BRAFTOVI shows improved response rates in colorectal cancer trial
-
-
-
-
-
-
-
Pfizer (PFE) PT Lowered to $27 at BofA Securities
-
-
-
-
-
-
-
Pfizer completes $7 billion acquisition of obesity drugmaker Metsera
-
-
-
-
-
-
-
Metsera declares Novo Nordisk's $10 billion bid superior to Pfizer offer
-
1,164,836 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

